Document is current
Any future updates will be listed below
-
Authors
Suzuki, Yuka
Miya, Aika https://orcid.org/0000-0002-3313-6946
Nakamura, Akinobu
Handa, Takahisa
Kameda, Hiraku
Atsumi, Tatsuya
- License Information
-
More Information
Article History
Received: 26 August 2024
Accepted: 23 January 2025
First Online: 7 February 2025
Declarations
:
: Tatsuya Atsumi received honoraria for writing promotional material for Janssen Pharmaceutical K.K. Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Pfizer Inc., Alexion Inc., Novartis Pharma K.K., Eli Lilly Japan K.K., AbbVie Inc., Nippon Boehringer Ingelheim Co., Ltd., UCB Japan Co. Ltd., AstraZeneca, Asahi Kasei Pharma Co. Ltd., Eisai Co., Ltd. He also received research grants from Asahi Kasei Pharma Co. Ltd., Otsuka Pharmaceutical Co. Nippon Boehringer Ingelheim Co., Ltd., TEIJIN PHARMA LIMITED., Eisai Co., Ltd., Eli Lilly Japan K.K. Alexion Inc., Mitsubishi Tanabe Pharma Co. Chugai Pharmaceutical Co., Ltd. Yuka Suzuki, Aika Miya, Akinobu Nakamura, Takahisa Handa, and Hiraku Kameda declare that they have no conflict of interest.
: Name of institutional ethical committee on human experimentation: The institutional review board of Hokkaido University Hospital. Date of approval: November 16, 2017. Approval number: 017-0147.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.
